CALGARY, Alberta, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces its participation in the upcoming BIO Investor Forum in San Francisco, CA. Mr. Donald J. McCaffrey, President and Chief Executive Officer, will provide a corporate update and overview of recent activities at the conference.
Presentation & Webcast Details:
Date: Tuesday, October 17th
Time: 11:15 am PT
Duration: ~15 minutes
Location: Elizabethan D Room at the Westin St. Francis
Webcast Link: Click hear to launch the webcast viewer
The presentation will be available on the Company’s website immediately prior to the start of the event. Click on this LINK to go directly to the appropriate page on the Company’s website. An archived replay of the webcast will also be available on the Company website by clicking on this LINK.
About Zenith
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (“mCRPC”).
For further information, please contact:
Clayton Paradis
Zenith Capital Corp.
Phone: 587-390-7865
Email: info@zenithepigenetics.com
Website: www.zenithepigenetics.com
